Related Experiment Video
Updated: Sep 3, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
Savvas Papageorgiou1, Sarah L Pashley1, Laura O'Regan1
1Department of Molecular and Cell Biology, University of Leicester, Lancaster Road, Leicester LE1 7RH, UK.
Abstract:
EML4-ALK is an oncogenic fusion protein that accounts for approximately 5% of NSCLC cases. Targeted inhibitors of ALK are the standard of care treatment, often leading to a good initial response. Sadly, some patients do not respond well, and most will develop resistance over time, emphasizing the need for alternative treatments. This review discusses recent advances in our understanding of the mechanisms behind EML4-ALK-driven NSCLC progression and the opportunities they present for alternative treatment options to ALK inhibitor monotherapy. Targeting ALK-dependent signalling pathways can overcome resistance that has developed due to mutations in the ALK catalytic domain, as well as through activation of bypass mechanisms that utilise the same pathways. We also consider evidence for polytherapy approaches that combine targeted inhibition of these pathways with ALK inhibitors. Lastly, we review combination approaches that use targeted inhibitors of ALK together with chemotherapy, radiotherapy or immunotherapy. Throughout this article, we highlight the importance of alternative breakpoints in the EML4 gene that result in the generation of distinct EML4-ALK variants with different biological and pathological properties and consider monotherapy and polytherapy approaches that may be selective to particular variants.
Insights
Discover new treatments for non-small cell lung cancer (NSCLC) driven by EML4-ALK. This review explores alternative therapies and combination strategies to overcome resistance to ALK inhibitors.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- EML4-ALK fusion protein drives approximately 5% of non-small cell lung cancer (NSCLC) cases.
- ALK inhibitors are standard treatment but face challenges with initial response and acquired resistance.
- Understanding EML4-ALK variants and resistance mechanisms is crucial for developing effective therapies.
Purpose of the Study:
- To review recent advances in EML4-ALK-driven NSCLC.
- To explore alternative treatment strategies beyond ALK inhibitor monotherapy.
- To discuss combination therapies including targeted agents, chemotherapy, radiotherapy, and immunotherapy.
Main Methods:
- Literature review of recent studies on EML4-ALK in NSCLC.
- Analysis of resistance mechanisms to ALK inhibitors.
- Evaluation of various therapeutic approaches, including monotherapy and polytherapy.
Main Results:
- Targeting ALK-dependent pathways can overcome resistance mutations and bypass activation.
- Polytherapy combining ALK inhibitors with other targeted agents shows promise.
- Combination strategies with chemotherapy, radiotherapy, or immunotherapy offer alternative treatment avenues.
- Different EML4-ALK variants may require variant-selective therapeutic approaches.
Conclusions:
- Alternative and combination therapies are essential to overcome resistance in EML4-ALK-driven NSCLC.
- Targeting specific pathways and considering EML4-ALK variant diversity can improve treatment outcomes.
- Further research into novel therapeutic strategies is warranted for patients with NSCLC harboring EML4-ALK fusions.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...